Phathom Pharmaceuticals, Inc. (PHAT) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Phathom Pharmaceuticals, Inc. (PHAT) closed at USD 7.50 on 2026-10-15, a change of -44.6 % over the past year, with a market capitalization of USD 559.83M.

Phathom Pharmaceuticals, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Phathom Pharmaceuticals, Inc. key figures

Previous close

USD 7.50 (2026-10-15)

1-year change

-44.6 %

Market cap

USD 559.83M

Enterprise value

USD 929.38M

P/E ratio (trailing)

-5.49

P/E ratio (forward)

6.43

EPS (trailing)

-1.26

EPS (forward)

1.08

PEG ratio

n/a

Price to book

-1.61

Revenue growth

88 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

8.00

Employees

371

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Phathom Pharmaceuticals, Inc.

Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases in the United States. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical trials for treating Helicobacter pylori, as well as VOQUEZNA and vonoprazan for the treatment of heartburn associated with non-erosive GERD and eosinophilic esophagitis in adults and adolescents. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Phathom Pharmaceuticals, Inc. and compare it with other stocks.